Drug class profile · refreshed daily from federal data

Prostaglandin E1 Analog

3 molecules in this class, $5.3M combined CY2024 Part D spend across 136K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Prostaglandin E1 Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $5.3Mcombined across class
Total Rx claims: 136K77K unique beneficiaries
Generic mfrs (active): 7across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Misoprostol

Brand: Cytotec · 136K Part D claims (CY24) · 77K beneficiaries · First FDA approval: 1986-12-27

3 generic mfrs 0 plans require PA

Low NADAC$0.472

→

Avg plan cost$0.640

Part D spend $5.3M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Dicloenac and Misoprostol

— Part D claims (CY24) · First FDA approval: 2023-02-16

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Diclofenac and Misoprostol

Brand: ARTHROTEC · — Part D claims (CY24) · First FDA approval: 1997-12-24

4 generic mfrs 0 plans require PA

Low NADAC$0.882

→

Avg plan cost$1.44

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.